ABSTRACT
The term thrombotic microangiopathy (TM) describes a clinical syndrome that spans across a broad landscape of disease entities and clinical settings. The hallmark features reflect common pathological manifestations of microvascular compromise, including microangiopathic hemolysis, thrombocytopenia, and organ dysfunction, in the absence of disseminated intravascular coagulation (1). The central and unifying element in this disease landscape is regional and specific microvascular endothelial injury. The operative pathogenetic mechanisms differ between individual patients sharing common clinical features.
